New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:50 EDTKERXKeryx announces submission of MAA for Zerenex to EMA
Keryx Biopharmaceuticals announced it has submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, seeking the approval of Zerenex as a treatment for hyperphosphatemia in patients with chronic kidney disease, or CKD, including dialysis- and non-dialysis dependent CKD. The MAA will be reviewed by the EMA Committee for Medicinal Products for Human Use and the review will be conducted under the Centralized Authorization Procedure. An approval under the Centralized Authorization Procedure provides one marketing authorization which is valid in all 27 member states of the European Union, as well as in Norway, Liechtenstein and Iceland.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
06:28 EDTKERXKeryx upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
September 25, 2015
07:06 EDTKERXKeryx price target lowered to $18 from $22 at Brean Capital
Subscribe for More Information
September 24, 2015
12:21 EDTKERXCiti says EU approval does not impact Sell on Keryx
Subscribe for More Information
09:05 EDTKERXOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
07:06 EDTKERXKeryx wins EU approval for Fexeric treatment of Hyperphosphatemia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use